ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2322

Toward Cardiovascular Risk Stratification in Rheumatoid Arthritis: Use of Regression Tree Analyses to Evaluate Impact of Serum Biomarkers and Cardiovascular Risk Factors on Carotid Intima Media Thickness

Kimberly Liang1, Yaming Li 1, Suresh Mulukutla 1, Steven Reis 1, Marc Levesque 1, Donald Jones 1, Rachel Gartland 1, Jennifer Avolio 1, Ali Hakim Shoushtari 1, Flordeliza Villanueva 1, Larry Moreland 1 and Douglas Landsittel 2, 1University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, RI

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: biomarkers and atherosclerosis, Cardiovascular disease, Rheumatoid arthritis (RA), risk assessment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Both traditional cardiovascular (CV) risk factors and disease-related factors contribute to the increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). Mechanisms of atherosclerosis include (1) Endothelial dysfunction/activation mediated by intercellular adhesion molecules (e.g., ICAM-1, VCAM-1, E-selectin), nitrite (NO), and oxidative stress (e.g., via MPO activity); (2) Inflammation mediated by cytokines (e.g., IL-6); (3) Plaque stability mediated by CD40-CD40L interactions; and (4) Proteolysis/Plaque rupture mediated by proteolytic enzymes (e.g. MMP-9). Inflammatory and immune biomarkers important in RA pathogenesis include erythrocyte sedimentation rate (ESR), C-reactive protein (hsCRP), and IL-17. This study seeks to develop easy to visualize decision rules for the differential effects of these serum biomarkers and CV risk factors on carotid intima-media thickness (cIMT) in RA vs. control subjects.

Methods: Carotid ultrasounds measured maximum cIMT and plaque presence, and serum biomarkers (ICAM-1, VCAM-1, E-selectin, NO, MPO, IL-6, CD40L, MMP-9, ESR, hsCRP, IL-17) were measured on 87 RA cases and 101 controls. All RA subjects met 2010 ACR classification criteria. CV risk factors (age, gender, race, obesity, hypertension (HTN), diabetes (DM), hyperlipidemia (HL), smoking (ever), personal and family history of CVD) were collected on all subjects. Regression tree models were applied with cIMT as the outcome measure, and all the serum biomarkers and significant (based on an unadjusted linear model) CV risk factors (age, gender, DM, smoking, personal history of CVD) as potential splits in the tree model. Tree models are built by identifying the best split across all values of all variables and partitioning the data into the two resulting subgroups (or nodes); within each subgroup the process is repeated until the nodes are too small (n< 10) to split further. The trees were also pruned by eliminating nodes (beginning with the lowest branches of the tree) that did not contribute significantly to model fit.

Results: Demographics were similar between RA and controls except for age (mean 59.6+/-12.0 in RA vs. 54.0+/-14.7 years in controls; p=0.005), as were CVD risk factors except for hypertension (46.4% in RA vs. 23.3% in controls). The tree models (Figures 1-2) display the mean cIMT (with the percent in that group) for each terminal node (e.g. final subgroups). For RA cases, Figure 1 shows that RA patients age 51 or older with CD40 < 8235 had the highest mean cIMT, especially for MPO ≥ 343 or for age 67 or older with MPO < 343 (0.98-1.19). In controls, males with ESR ≥ 11 and female smokers age 34 or older with eSelectin ≥ 38.1 had the highest mean cIMT (0.86-1.09).

Conclusion: This study reveals that RA and control subjects have differential contributing effects of various serum inflammatory and vascular biomarkers and traditional CV risk factors on subclinical atherosclerosis risk, as measured by cIMT. Results may inform future studies to develop additional CVD risk stratification algorithms in RA patients.


ACR 2019 abstract_tree models Figure 1

Figure 1 – Pruned Regression Tree for the RA Group


ACR 2019 abstract_tree models Figure 2

Figure 2 – Pruned Regression Tree for the Control Group


Disclosure: K. Liang, None; Y. Li, None; S. Mulukutla, None; S. Reis, None; M. Levesque, None; D. Jones, None; R. Gartland, None; J. Avolio, None; A. Hakim Shoushtari, None; F. Villanueva, None; L. Moreland, None; D. Landsittel, None.

To cite this abstract in AMA style:

Liang K, Li Y, Mulukutla S, Reis S, Levesque M, Jones D, Gartland R, Avolio J, Hakim Shoushtari A, Villanueva F, Moreland L, Landsittel D. Toward Cardiovascular Risk Stratification in Rheumatoid Arthritis: Use of Regression Tree Analyses to Evaluate Impact of Serum Biomarkers and Cardiovascular Risk Factors on Carotid Intima Media Thickness [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/toward-cardiovascular-risk-stratification-in-rheumatoid-arthritis-use-of-regression-tree-analyses-to-evaluate-impact-of-serum-biomarkers-and-cardiovascular-risk-factors-on-carotid-intima-media-thickn/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/toward-cardiovascular-risk-stratification-in-rheumatoid-arthritis-use-of-regression-tree-analyses-to-evaluate-impact-of-serum-biomarkers-and-cardiovascular-risk-factors-on-carotid-intima-media-thickn/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology